Agios strategy shift pays off with FDA approval of first drug for rare anemia February 18, 2022 Auto Bot Anemia, BioPharma, Cambridge, Clinical Trials, FDA, Legal, Massachusetts, Pharma, Rare diseases 0 Agios Pharmaceuticals has its third FDA-approved product, and the first under its new rare disease strategy. The regulatory decision also marks the first approved treatment for pyruvate kinase deficiency, a rare disease that leads to chronic anemia.